HOT TOPICS - ANNEXA-I Trial Neurocritical Care Society podcast

Artwork

Criticalcare Neurocriticalcare Fitness Neurocritical Care Society Education Neurocritical Care Neurology Science Medicine

内容由Education Neurocritical Care and Neurocritical Care Society提供。所有播客内容（包括剧集、图形和播客描述）均由 Education Neurocritical Care and Neurocritical Care Society 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

Neurocritical Care Society Podcast « »
HOT TOPICS - ANNEXA-I Trial

5M ago 1:01:20

分享

MP4•单集首页

内容由Education Neurocritical Care and Neurocritical Care Society提供。所有播客内容（包括剧集、图形和播客描述）均由 Education Neurocritical Care and Neurocritical Care Society 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.

… continue reading

102集单集

#Criticalcare #Neurocriticalcare #Fitness #Neurocritical Care Society #Education Neurocritical Care #Neurology #Science #Medicine

Artwork

HOT TOPICS - ANNEXA-I Trial

Neurocritical Care Society Podcast

86 subscribers

published 5M ago

分享

MP4•单集首页

内容由Education Neurocritical Care and Neurocritical Care Society提供。所有播客内容（包括剧集、图形和播客描述）均由 Education Neurocritical Care and Neurocritical Care Society 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.

… continue reading

102集单集

#Criticalcare #Neurocriticalcare #Fitness #Neurocritical Care Society #Education Neurocritical Care #Neurology #Science #Medicine

Toate episoadele

×

欢迎使用Player FM

Player FM正在网上搜索高质量的播客，以便您现在享受。它是最好的播客应用程序，适用于安卓、iPhone和网络。注册以跨设备同步订阅。

收听超过500个主题